Views

CrossRef citations to date

Altmetric

Original Article

Exploring QSARs of some benzenesulfonamides incorporating cyanoacrylamide moieties as a carbonic anhydrase inhibitors (specifically against tumor-associated isoforms IX and XII)

Ahmed M. AlafeefyDepartment of Pharmaceutical Chemistry, College of Pharmacy, Salman Bin Abdulaziz University, Alkharj, Saudi Arabia,

Hatem A. Abdel-AzizDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia, ;Department of Applied Organic Chemistry, National Research Center, Dokki, Cairo, Egypt,

F. CartaDepartment of Chemistry, Università degli Studi di Firenze, Polo Scientifico, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, Sesto Fiorentino (Florence), Italy, ;Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Università degli Studi di Firenze, Sesto Fiorentino (Florence), Italy, and

Claudiu T. SupuranDepartment of Chemistry, Università degli Studi di Firenze, Polo Scientifico, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, Sesto Fiorentino (Florence), Italy, ;Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Università degli Studi di Firenze, Sesto Fiorentino (Florence), Italy, and

Shilendra K. PathakDepartment of Physics, University of Lucknow, Lucknow, India

Onkar PrasadDepartment of Physics, University of Lucknow, Lucknow, India

Leena SinhaDepartment of Physics, University of Lucknow, Lucknow, IndiaCorrespondence[email protected]

show all

Figures & data

Table 1. Benzenesulfonamides incorporating cyanoacrylamide moieties used for QSAR analysis against hCA IX and XII.

Display Table

Table 2. Experimental and predicted inhibition constants of benzenesulfonamides against human carbonic anhydrase (hCA) isoforms IX and XII along with residuals.

Download CSV Display Table

Table 3. Cross-validation parameters.

Display Table

Figure 1. Plot of the predicted inhibitory constant for hCA IX against observed one using model 1.

Figure 2. Plot of the predicted inhibitory constant for hCA XII against observed one using model 2.

Supplemental material

Supplemental Material.pdf

Download PDF (37.1 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Exploring QSARs of some benzenesulfonamides incorporating cyanoacrylamide moieties as a carbonic anhydrase inhibitors (specifically against tumor-associated isoforms IX and XII)

Table 1. Benzenesulfonamides incorporating cyanoacrylamide moieties used for QSAR analysis against hCA IX and XII.

Table 2. Experimental and predicted inhibition constants of benzenesulfonamides against human carbonic anhydrase (hCA) isoforms IX and XII along with residuals.

Table 3. Cross-validation parameters.

Supplemental Material.pdf

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Exploring QSARs of some benzenesulfonamides incorporating cyanoacrylamide moieties as a carbonic anhydrase inhibitors (specifically against tumor-associated isoforms IX and XII)

Figures & data

Table 1. Benzenesulfonamides incorporating cyanoacrylamide moieties used for QSAR analysis against hCA IX and XII.

Table 2. Experimental and predicted inhibition constants of benzenesulfonamides against human carbonic anhydrase (hCA) isoforms IX and XII along with residuals.

Table 3. Cross-validation parameters.

Supplemental Material.pdf

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date